Wednesday, February 20, 2019 12:52:23 PM
None of any substance known, short term, other than chief executive officer, Brian Lian, will deliver a corporate presentation at the 11th Annual Biotech Showcase™ later in the month.........long term, the company is prepping for more biopsy testing of its drugs, both VK2809 in NASH and VK5211, “an orally available, non-steroidal SARM designed to selectively stimulate muscle and bone formation.”.
However, as this is a close knit sector with limited current players possessing potential for FDA approval. A buy-out offer is always an immediate possibility, that along with any positive new from others seems to move the top potentials in the sector as a whole, although temporarily when it happens.
GO VKTX
"PEACE"
Question...is there a short term catalyst or forward event coming thanks
'bUrRpPPP!'
However, as this is a close knit sector with limited current players possessing potential for FDA approval. A buy-out offer is always an immediate possibility, that along with any positive new from others seems to move the top potentials in the sector as a whole, although temporarily when it happens.
GO VKTX
"PEACE"
Recent VKTX News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/01/2026 08:16:27 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/01/2026 08:15:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/01/2026 08:14:56 PM
- Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 • PR Newswire (US) • 03/26/2026 11:05:00 AM
- Viking Therapeutics to Participate at Upcoming Investor Conferences • PR Newswire (US) • 03/05/2026 09:03:00 PM
- Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market • PR Newswire (US) • 02/13/2026 04:26:00 PM
- Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market • PR Newswire (Canada) • 02/13/2026 04:26:00 PM
- Viking Therapeutics jumps nearly 12% on plans to move oral obesity drug into Phase 3 • IH Market News • 02/12/2026 02:48:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/11/2026 10:25:49 PM
- Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update • PR Newswire (US) • 02/11/2026 09:16:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:06:25 PM
- Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026 • PR Newswire (US) • 02/04/2026 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/27/2026 12:57:19 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/27/2026 12:55:53 AM
- Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity • PR Newswire (US) • 01/12/2026 12:00:00 PM
- Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity • PR Newswire (US) • 01/08/2026 12:00:00 PM
- Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer • PR Newswire (US) • 01/07/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 01:31:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 01:28:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 01:24:52 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/05/2026 09:32:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/05/2026 09:30:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/05/2026 09:29:42 PM
- Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/05/2026 09:03:00 PM
- The End of Shots? 5 Biotech Stocks Rethinking Diabetes • PR Newswire (US) • 12/31/2025 01:07:00 PM
